PubMed Health⌕ Search

Biomedical subjects

A Klingner

Publications and source records attributed to A Klingner.

16 recordsLinked to original sources
PubMed1979

Amantadine in senile dementia: electroencephalographic and clinical effects.

Nineteen patients with senile brain disease (including 2 with parkinsonian symptoms) were treated with amantadine in an oral dosage of 200--300 mg daily. Seven showed definite clinical benefits such as increased alertness and decreased agitation, and 2 others showed slight benefits. However, in only one instance was the benefit maintained without complications. Toxic effects such as overactivity, anxiety and visual hallucinations were observed in 8 patients. Withdrawal effects (e.g., lethargy and staggering) occurred when amantadine was discontinued. The electroencephalograms (EEGs) of all 19 patients showed a frequency increase, chiefly of occipital alpha activity, and sometimes a return to normal, irrespective of clinical changes. Toxic side effects were associated with particularly prominent EEG acceleration. In 10 of the 19 patients, the clinical changes were further validated by by additional psychologic assessments. Although the value of amantadine is limited when given in this way to patients with senile brain disease, it seems important to observe its effects in drug combinations aimed at correction of neurotransmitter imbalances.

Administration, Oral↗
PubMed1979

A psychogeriatric assessment program. V. Three-year follow-up.

In 1974, a 10-month diagnostic evaluation of 80 newly admitted psychogeriatric patients was undertaken. The diagnostic categories were functional versus organic brain disease. The present report deals with results of a follow-up evaluation three years later. To assess the prognostic validity of our measures, the initial 1974 data on survivor and nonsurvivor groups were studied, and some of the tests were repeated in 35 of the 40 survivors. Statistically significant differences between survivors and nonsurvivors were found in both "organic" and "functional" groups, with respect to performance on psychologic and psychophysiologic tests, and the level of social functioning before admission. The death rate was significantly higher in the group with organic disease.

Aged↗
PubMed1977

Clomipramine (Anafranil) and behaviour therapy in obsessive-compulsive and phobic disorders.

In a comparative study of three treatment regimens in patients with obsessive-compulsive or phobic manifestations, the most favourable therapeutic findings were seen in the clomipramine (Anafranil, Geigy Pharmaceuticals) plus behaviour therapy group and the least favourable therapeutic findings in the clomipramine plus simulated behaviour therapy group. The findings that a combination of behaviour therapy and clomipramine results in more favourable therapeutic changes than either of the two treatments alone is in line with reported studies in the literature.

Adult↗
PubMed1976

A psychogeriatric assessment program. III. Clinical and experimental psychologic aspects.

Variables stemming from standard psychologic tests, psychophysiologic tests, and operant conditioning procedures were employed in assessing the status of 80 psychogeriatric patients with either organic brain syndromes or functional psychoses. Differences were observed in the responses between the two groups. In general, the performance of the patients with organic brain syndromes was more deviant than that of the patients with functional psychoses, and the performance of the hospitalized geriatric patients (regardless of diagnosis) was worse than that of the normal control groups.

Adolescent↗
PubMed1976

A psychogeriatric assessment program. IV. Interdisciplinary aspects.

The interdisciplinary aspects of the psychogeriatric assessments described in three previous papers are discussed on the basis of factor-analysis findings and their significance in diagnosis, treatment, planning and theory. The difference between basic biopsychologic dysfunctions (including pathohistologic changes and various counter-regulations) and psychosocial dysfunctions (lifestyle) becomes clear statistically as well as clinically. This difference probably is fundamental, in the sense that intact biopsychologic functions are elementary tools for the psychosocial functions.

Aged↗
PubMed1975

A clinical trial with nomifensin, a new antidepressant drug.

An uncontrolled clinical trial with 10 depressed patients was conducted to identify the psychopathological symptoms which may be affected by nomifensin administration, and to reveal the possible adverse effects of the drug. Consistent statistically significant improvement was noted in the course of the clinical trial on all of the assessment instruments used, and - with the exception of one patient - all improved while receiving nomifensin. Most of the therapeutic changes were seen within the first three weeks of treatment, and they included improvements of depression, as well as of hostility, a symptom which usually remains unaffeCTED BY TRICYclic antidepressant drugs. To verify the favorable therapeutic effects of nomifensin in depressed psychiatric patients, a standard-controlled clinical trial is in progress; and to verify the action mechanism of nomifensin, a study employing the probenecid technique and the measurement of spinal homovanillic acid (HVA) and 5-hydroxyindole acetic acid (5hiaa) concentration is planned.

Adjustment Disorders↗